Halozyme Therapeutics (HALO) Depreciation & Amortization (CF) (2016 - 2025)
Halozyme Therapeutics (HALO) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $3.3 million as the latest value for Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 24.54% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.4 million through Dec 2025, up 10.76% year-over-year, with the annual reading at $11.4 million for FY2025, 10.97% up from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 was $3.3 million at Halozyme Therapeutics, up from $2.7 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $3.3 million in Q4 2025, with the low at $700000.0 in Q1 2021.
- Average Depreciation & Amortization (CF) over 5 years is $2.1 million, with a median of $2.6 million recorded in 2022.
- The sharpest move saw Depreciation & Amortization (CF) dropped 18.32% in 2021, then skyrocketed 234.19% in 2023.
- Over 5 years, Depreciation & Amortization (CF) stood at $800000.0 in 2021, then surged by 225.0% to $2.6 million in 2022, then rose by 10.88% to $2.9 million in 2023, then dropped by 7.98% to $2.7 million in 2024, then rose by 24.54% to $3.3 million in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $3.3 million, $2.7 million, and $2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.